Celldex Therapeutics Inc. research snapshot
CLDX AI stock analysis reads Celldex Therapeutics as a clinical-stage biotechnology company whose lead asset, barzolvolimab, depletes mast cells by targeting the KIT receptor. The stock closed at $37.69 on August 3, 2026, implying a market cap of about $2.96 billion on 78.49 million shares. On July 21, 2026 the company discontinued its Phase 2 program in prurigo nodularis after the study missed primary and key secondary endpoints, narrowing the thesis to chronic spontaneous urticaria (CSU), where Phase 3 topline data is expected in September or October 2026. Celldex holds about $451 million in cash against roughly $3 million of debt. This page is informational research and is not investment advice.
Current price
$37.69 close on August 3, 2026
Market cap
$2.96 billion using 78.49 million shares; price times shares verified with 0.06% variance via financial_rigor.py
AI score
38 / 100
Rating
KIT-targeting antibody platform now focused on a late-stage CSU asset after discontinuing prurigo nodularis, offset by pre-revenue status, concentrated single-asset dependency, elevated short interest, and binary Phase 3 CSU data expected in September or October 2026
Trend status
Price is below the 52-week high of $40.30, up roughly 40% YTD and 73% over the past year, with short interest near 9.8% of shares outstanding and 10.6% of float
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Celldex develops antibody therapies that target mast cells through the KIT receptor for allergic, inflammatory, and autoimmune diseases. The lead asset barzolvolimab is in Phase 3 for CSU, with additional Phase 3 programs in cold urticaria and symptomatic dermographism, a Phase 2 program in atopic dermatitis, and an early bispecific candidate, CDX-622. The prurigo nodularis program was discontinued in July 2026 after a Phase 2 miss. | Medium |
| Moat | The moat comes from KIT biology expertise, barzolvolimab differentiation as a mast cell-depleting antibody versus current symptomatic CSU therapies, and issued and pending patents. The July 2026 failure in prurigo nodularis narrowed the claimed scope of mast cell biology in skin disease, while competitors including Novartis (remibrutinib) and Roche Xolair biosimilars could still erode the addressable market in CSU. | Low-medium |
| Management | Founder-led management with Anthony Marucci as CEO since the company was founded and Tibor Keler as Chief Scientific Officer. CFO Sam Martin has announced plans to retire in 2027 after serving since 2017. Commercial buildout under Teri Lawver signals preparation for a potential barzolvolimab launch, but the team must now execute on CSU Phase 3 readouts after the prurigo nodularis setback. | Medium |
| Financial trend | Balance sheet shows $451.46 million in cash and short-term investments against roughly $3 million of total debt as of March 31, 2026, providing estimated runway into 2029. TTM net loss is $283.65 million and TTM free cash flow is negative $226.25 million, reflecting significant but expected clinical-stage cash burn. | High |
| Valuation | At $37.69 and a $2.96 billion market cap, CLDX trades at about 5.5x book value with no PE ratio due to negative earnings. Enterprise value of roughly $2.51 billion against near-zero revenue implies the market prices in a significant barzolvolimab CSU approval probability. Risk/reward is asymmetric: large upside if Phase 3 CSU succeeds, significant downside if it fails. | Low-medium |
| Technical trend | CLDX closed at $37.69 on August 3, 2026, below the 52-week high of $40.30 but above both the 50-day moving average near $34.25 and the 200-day moving average near $29.71. RSI is around 58.6 and short interest remains elevated at 9.76% of shares outstanding. | Medium |
| Risk level | Key risks are Phase 3 CSU failure or delay after the prurigo nodularis miss, regulatory rejection, slow commercial adoption, competitive pressure from remibrutinib and biosimilar Xolair, single-asset concentration, equity dilution, and short interest near 9.8% of shares outstanding. | Medium-high |
| AI confidence | High for cash position, share count, market cap math, reported financials, and short interest. Medium for pipeline probability-adjusted scenarios because approval timelines and commercial adoption depend on binary clinical outcomes. | High for financials, medium for scenarios |
| Investment certainty | Low to medium. The stock prices in a significant CSU approval probability and the July 2026 prurigo nodularis failure raised the market sensitivity to the upcoming Phase 3 CSU readouts. Investors need a clear view on trial success probability and post-approval commercial adoption. | Low-medium |
CLDX AI stock forecast
The CLDX AI stock forecast uses scenario ranges around the $37.69 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires successful barzolvolimab Phase 3 CSU data in September or October 2026, FDA approval (potential 2027 to 2028 launch), and pipeline expansion. The base case assumes approval but slower-than-expected commercial uptake. The bearish case assumes Phase 3 failure, similar to the prurigo nodularis outcome, or significant competitive erosion.
$75 to $110
More likely if barzolvolimab Phase 3 CSU trials meet primary endpoints with strong safety, FDA approval follows in 2027 to 2028, peak sales estimates exceed $2 billion, pipeline expansion into atopic dermatitis and cold urticaria adds value, and CLDX avoids significant dilution.
$32 to $48
More likely if barzolvolimab is approved for CSU but initial uptake is gradual, competitive pressure from remibrutinib and Xolair biosimilars limits market share, cash burn continues at current pace, and pipeline programs advance more slowly than expected.
$8 to $18
More likely if Phase 3 CSU data disappoints, barzolvolimab fails to show meaningful differentiation versus standard of care, FDA requires additional trials delaying approval by 2 to 3 years, or safety signals emerge that limit the addressable patient population.
CLDX AI technical analysis
CLDX AI technical analysis starts from the $37.69 August 3 close used for this August 4 static page. The stock is below its 52-week high of $40.30 after pulling back around the July 2026 prurigo nodularis news, but remains above both its 50-day and 200-day moving averages. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $37.69 | Latest verified close used for this page as of the August 4, 2026 data cutoff. |
| Near support | $34 to $35 | Support zone around the 50-day moving average area near $34.25 based on recent price action. |
| Secondary support | $29.50 to $31 | The 200-day moving average area near $29.71. A sustained break below would weaken the longer-term technical setup. |
| Near resistance | $40 to $42 | The 52-week high zone at $40.30. A breakout above $42 with volume would signal renewed momentum ahead of the CSU catalyst. |
| 50-day moving average | About $34.25 | Public technical sources showed CLDX above the 50-day moving average around the cutoff. |
| 200-day moving average | About $29.71 | CLDX is well above the 200-day moving average, supporting the longer-term uptrend. |
| Momentum | RSI around 58.6, neutral to bullish | RSI near 58.6 after the recent pullback reflects neutral to bullish momentum. The stock is below its 52-week high after the July 2026 setback, so momentum depends on the upcoming CSU catalyst. |
| Volume | About 1.0 to 1.6 million shares average daily | Average 20-day volume was about 1.02 million shares, with a spike on the July 21, 2026 prurigo nodularis news day. A CSU data release is likely to bring a volume surge. |
| Volatility | Beta 0.90, elevated biotech event risk | CLDX beta is moderate but the stock has shown sharp moves on clinical data releases, as seen around the July 21, 2026 prurigo nodularis announcement. Position sizing should account for binary event risk. |
| Invalidation | Close below $34, then $29.50 | A close below the 50-day area weakens near-term momentum. A break below the 200-day area would challenge the longer-term bullish trend. |
CLDX AI trading strategy
The CLDX AI trading strategy is a rules-based framework, not personalized advice. It combines clinical pipeline evidence, technical confirmation, position sizing for binary event risk, and clear invalidation levels.
Track the Phase 3 CSU topline data expected in September or October 2026 and the regulatory milestone after that. Consider accumulating on weakness toward support zones only if the CSU and cash runway thesis remains intact.
Binary clinical outcomes create gap risk. No position should be sized larger than what can tolerate a 50% loss. Define maximum loss before any catalyst event such as the CSU data release.
Look for CLDX to hold above the 50-day moving average near $34.25 and break above $40 to $42 resistance with improving volume. Confirmation should include positive clinical news flow and analyst support.
A failed breakout or daily close below the 50-day area should reduce confidence. A break below the 200-day area near $29.71 would signal a trend change.
Track Phase 3 CSU enrollment and topline readouts, cash runway updates, feedback on barzolvolimab differentiation, competitive developments from remibrutinib and Xolair biosimilars, and the search for a successor to the retiring CFO.
Reduce or exit if the Phase 3 trial design raises risk, cash runway shortens significantly, competitive data weakens the barzolvolimab differentiation thesis, or additional pipeline setbacks emerge.
Investment research summary
Celldex develops antibody therapeutics that target mast cells to treat chronic allergic and inflammatory skin diseases. Patients pay for symptom relief in conditions like chronic urticaria where current options are inadequate, and the company aims to lead a new category of mast cell directed therapies.
The moat is built on KIT biology expertise, barzolvolimab first-in-class potential as a mast cell-depleting antibody, and issued patents. Differentiation comes from targeting the root cause (mast cells) versus symptomatic treatment. The moat is uncertain because the July 2026 prurigo nodularis failure narrowed the validated disease scope, and competitors with different mechanisms (BTK inhibitors, anti-IgE biosimilars) could erode the addressable market.
The thesis can fail if Phase 3 CSU data does not replicate Phase 2 results, as happened with prurigo nodularis, if FDA requires additional trials or issues a complete response letter, if commercial adoption is slow due to reimbursement or physician inertia, if competitors launch with better profiles, or if the company dilutes shareholders to fund operations.
Founder Tony Marucci has led Celldex since its 2004 founding, demonstrating long-term commitment. Scientific leadership under Tibor Keler is strong. The commercial buildout under Teri Lawver signals preparation for a potential launch, while CFO Sam Martin plans to retire in 2027. Key risk is whether the team can navigate the CSU Phase 3 readouts and then transition from R&D to commercial execution.
Celldex operates in the immunology and inflammatory disease market, specifically mast cell-mediated conditions. The trend favors targeted biologics over broad immunosuppressants. CSU affects 1 to 3% of the global population, with unmet need for patients who fail antihistamines and Xolair, but the prurigo nodularis failure showed mast cell depletion is not a universal solution across skin diseases.
At $2.96 billion market cap with near-zero revenue and negative earnings, the stock prices in a significant barzolvolimab CSU approval probability. There is no traditional margin of safety. The payoff is asymmetric: large upside on success, deep downside on failure, and investors should size accordingly.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CLDX price | $37.69 close on August 3, 2026 | StockAnalysis and Yahoo Finance quote snapshots | August 4, 2026 |
| Market capitalization | $2.96 billion, verified as $37.69 x 78,490,000 shares | financial_rigor.py market cap verification and SEC filings | August 4, 2026 |
| Cash and short-term investments | $451.46 million as of Q1 2026 (March 31, 2026) | StockAnalysis balance sheet and Yahoo Finance, cross-verified with 0.00% variance | August 4, 2026 |
| Total debt | About $3.1 million including current portion and leases | StockAnalysis balance sheet data | August 4, 2026 |
| TTM revenue | $865,000 | StockAnalysis and SEC filings | August 4, 2026 |
| TTM net loss | -$283.65 million | StockAnalysis income statement | August 4, 2026 |
| EPS (TTM) | -$4.27 | financial_rigor.py valuation verification | August 4, 2026 |
| Shares outstanding | 78.49 million | StockAnalysis and Yahoo Finance | August 4, 2026 |
| 52-week range | $19.72 to $40.30 | StockAnalysis and Yahoo Finance | August 4, 2026 |
| Moving averages | 50-day about $34.25, 200-day about $29.71 | StockAnalysis statistics | August 4, 2026 |
| Short interest | 7.66 million shares, 9.76% of shares outstanding, 10.58% of float, 5.80 days to cover | StockAnalysis short interest data | August 4, 2026 |
| Analyst consensus | Strong Buy, average price target $57.07 with a range of $34 to $100 from 16 analysts | StockAnalysis forecast (S&P Global and TipRanks data) | August 4, 2026 |
This CLDX AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 4, 2026 and can be wrong. Biotech stocks carry binary clinical and regulatory risk, and the July 2026 prurigo nodularis setback is a reminder that trial outcomes are uncertain. Past stock performance does not guarantee future results.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
